Fibromyalgia - Pipeline Review, H1 2018 - Product Image

Fibromyalgia - Pipeline Review, H1 2018

  • ID: 4451682
  • Report
  • 68 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aptinyx Inc
  • Astellas Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Intec Pharma Ltd
  • KPI Therapeutics Inc
  • Merck & Co Inc
  • MORE
Fibromyalgia - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H1 2018, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 2, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System)
  • The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aptinyx Inc
  • Astellas Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Intec Pharma Ltd
  • KPI Therapeutics Inc
  • Merck & Co Inc
  • MORE
Introduction

Fibromyalgia - Overview

Fibromyalgia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fibromyalgia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibromyalgia - Companies Involved in Therapeutics Development

Aptinyx Inc

Astellas Pharma Inc

Daiichi Sankyo Co Ltd

Innovative Med Concepts LLC

Intec Pharma Ltd

Jiangsu Hengrui Medicine Co Ltd

KPI Therapeutics Inc

Merck & Co Inc

Pfizer Inc

Prismic Pharmaceuticals Inc

Switch Biotech LLC

Fibromyalgia - Drug Profiles

(cannabidiol + dronabinol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(celecoxib + famciclovir) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-1069562 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0819 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-8062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirogabalin besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirtazapine ODT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYX-2925 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palmidrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SWT-06101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

U-2902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VNP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibromyalgia - Dormant Projects

Fibromyalgia - Discontinued Products

Fibromyalgia - Product Development Milestones

Featured News & Press Releases

Aug 01, 2017: Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions

Jun 30, 2017: Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes

Mar 22, 2017: Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies

Mar 07, 2017: Journal of Pain Research Publishes Results of PRID-201, a successful Phase 2 Trial using IMC-1 for the Treatment of Fibromyalgia

Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia

Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin

Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study

Nov 27, 2012: Intellipharmaceutics Announces Results Of Initial Phase I Clinical Trial Of Controlled-release Pregabalin

Nov 19, 2012: Pfizer Reports Top-line Results Of Phase III Study Evaluating Pregabalin Controlled-release As Treatment For Patients With Fibromyalgia

Jul 23, 2012: Pfizer Reports Top-Line Results Of EU Post-Authorization Safety And Efficacy Study Of Lyrica’s Discontinuation Effects In Patients With Generalized Anxiety Disorder

Feb 02, 2009: UCB Announces Top-Line Outcomes For Proof-Of-Concept Studies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Fibromyalgia, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Fibromyalgia - Pipeline by Aptinyx Inc, H1

Fibromyalgia - Pipeline by Astellas Pharma Inc, H1

Fibromyalgia - Pipeline by Daiichi Sankyo Co Ltd, H1

Fibromyalgia - Pipeline by Innovative Med Concepts LLC, H1

Fibromyalgia - Pipeline by Intec Pharma Ltd, H1

Fibromyalgia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1

Fibromyalgia - Pipeline by KPI Therapeutics Inc, H1

Fibromyalgia - Pipeline by Merck & Co Inc, H1

Fibromyalgia - Pipeline by Pfizer Inc, H1

Fibromyalgia - Pipeline by Prismic Pharmaceuticals Inc, H1

Fibromyalgia - Pipeline by Switch Biotech LLC, H1

Fibromyalgia - Dormant Projects, H1

Fibromyalgia - Discontinued Products, H1

List of Figures

Number of Products under Development for Fibromyalgia, H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aptinyx Inc
  • Astellas Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Innovative Med Concepts LLC
  • Intec Pharma Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • KPI Therapeutics Inc
  • Merck & Co Inc
  • Pfizer Inc
  • Prismic Pharmaceuticals Inc
  • Switch Biotech LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll